
Streamlined an early-phase oncology spinout’s IND-enabling workflow, reducing time-to-submission by 40% and improving FDA alignment through biomarker-driven study design.

Designed a dual-AAV preclinical plan and biomarker roadmap that supported seamless IND preparation for a gene therapy startup.

Converted exploratory mouse model data into a GLP-aware regulatory study package adopted by a partnering CRO.
Coming soon: CellGene IND Navigator™ - a proprietary framework to assess and accelerate IND readiness across preclinical and regulatory milestones.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.